Our Take
This is a CDMO partnership announcement with no product launches, clinical data, or independent benchmarks—it positions two suppliers as capacity partners in a market that exists mostly in pitch decks.
Why it matters
Peptide drug conjugates remain pre-commercial, but the $13.6bn ADC market (per GlobalData, 2024) has convinced major pharma that peptide-based conjugates are worth funding. Manufacturing complexity is real; so is the ability of specialist suppliers to capture margin while the field matures.
Do this week
Drug development teams evaluating PDC manufacturing: request process development timelines and OEB6 containment specs from both partners before committing to a CDMO RFP.
Two European suppliers align on peptide drug conjugates
Indena, an Italian manufacturer of active pharmaceutical ingredients, and Chemi S.p.A. (part of Italfarmaco Group) have announced a partnership to develop and manufacture peptide drug conjugates (PDCs) for biotech and pharmaceutical clients. Under the agreement, Chemi supplies peptides while Indena handles conjugation with highly potent payload molecules and GMP manufacturing.
Neither company is developing proprietary PDC drugs. Both are positioning themselves as development and manufacturing partners for external clients. Indena has recently upgraded its Milan facility to support targeted GMP drug conjugate manufacturing with OEB6 containment (the highest occupational exposure band for hazardous compounds).
The partnership reflects broader industry momentum. PeptiDream, Tandem Therapeutics, AnexAPep, and major pharma including Merck, Lilly, and Genentech are active in PDC research. Genentech signed a radiopharmaceutical partnership with PeptiDream in 2023 valued at approximately $1bn (company-reported); earlier PeptiDream deals with Merck and Eli Lilly were valued at roughly $2bn and $1bn respectively.
The ADC playbook is driving PDC expectations
PDCs are hybrid molecules composed of a targeting peptide, a chemical linker, and a therapeutic payload. They deliver highly potent drugs to target cells with greater precision than conventional therapies. The key difference from antibody drug conjugates (ADCs) is scale and accessibility: peptides are significantly smaller than monoclonal antibodies, potentially improving tumor penetration and targeting disease sites that larger antibody-based therapies cannot reach. Peptides can also be easier to produce and scale than biologic antibodies, potentially reducing manufacturing complexity and cost.
The global ADC market expanded from approximately $1.6bn in 2017 to reach $13.6bn in 2024 (per GlobalData Epidemiology and Market Size Database). That trajectory has convinced pharmaceutical companies that PDCs—despite being earlier-stage—are part of the next wave of targeted oncology therapeutics. The broader peptide therapeutics market is projected to reach more than $80bn by 2032 (analyst estimate), driven by oncology, obesity, diabetes, and rare disease applications.
Manufacturing expertise has become equally critical to discovery. Developing PDCs requires fluency in peptide synthesis, linker chemistry, payload engineering, analytical validation, containment systems, and GMP manufacturing. Few companies possess all these capabilities internally. Specialized CDMO partnerships allow drug developers to compress timelines by running analytical method development, pilot production, process optimization, and regulatory preparation in parallel rather than sequentially.
What this means for PDC development teams
The Indena-Chemi partnership signals that Western manufacturing capacity for complex peptides and HPAPIs is becoming a competitive differentiator. Demand for reliable GMP infrastructure, transparent manufacturing processes, and supply-chain resilience is rising among developers of advanced therapeutics.
For biotech companies evaluating PDC manufacturing partners, the partnership reinforces a structural shift: integrated capability (peptide synthesis through conjugation through GMP scale-up) is increasingly valuable, and development timelines hinge on supplier capacity and process maturity rather than chemistry innovation alone. The modular nature of peptide-based systems also creates flexibility to combine different targeting peptides with different payloads depending on disease context, broadening the addressable market beyond oncology.
The competitive landscape remains fragmented. No single company dominates. China is rapidly expanding its peptide and conjugate-drug pipeline, while Pfizer, Roche/Genentech, Lilly, and Merck continue to advance programs with greater clinical maturity. For suppliers like Indena and Chemi, the opportunity lies not in sponsoring branded therapies but in becoming the infrastructure that turns laboratory concepts into scalable manufacturing and clinical supply.